Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase Ib/II study to assess the safety, tolerability and preliminary efficacy of
AK119 combined with AK112 in patients with advanced solid tumors.